Adjuvant Therapy Considerations in Renal Cell Carcinoma

The conversation turns to the growing role of adjuvant therapy following surgical resection in high-risk localized or locally advanced RCC. Recent trials have demonstrated that systemic treatment in this setting can delay recurrence and potentially improve long-term outcomes. Panelists highlight ongoing debates regarding patient selection, timing, and optimal duration of therapy.

Adjuvant management is guided by risk assessment, which incorporates tumor stage, histology, and performance status. Multidisciplinary collaboration ensures that patients most likely to benefit from systemic treatment are identified early. The discussion emphasizes that close surveillance remains appropriate for some patients, especially when recurrence risk is moderate or treatment tolerance is uncertain.

Panelists conclude that continued clinical research and real-world experience will refine adjuvant strategies, balancing relapse prevention with quality of life and toxicity considerations.